Miodrag C Ostojic1, Zoran Perisic2, Dragan Sagic3, Robert Jung4, Yan-Ling Zhang5, Jamie Bendrick-Peart6, Ronald Betts7, Uwe Christians5. 1. Medical School, University of Belgrade and Clinical Center of Serbia, Division of Cardiology, Dr Subotic street 8, 11000, Belgrade, Serbia. mostojic2003@yahoo.com. 2. Clinical Centre Nis, Nis, Serbia. 3. Institute for Cardiovascular Disease Dedinje, Belgrade, Serbia. 4. Institute for Cardiovascular Disease, Sremska Kamenica, Serbia. 5. Clinical Research & Development, Department of Anesthesiology, University of Colorado Denver, Denver, CO, USA. 6. Eurofins Medinet, Aurora, CO, USA. 7. Biosensors International-USA, Newport Beach, CA, USA.
Abstract
OBJECTIVES: This prospective, open-label multicenter study was conducted to assess the pharmacokinetics of Biolimus A9 after elution from BioMatrix II coronary stents. Recent clinical trials have demonstrated the efficacy and safety of Biolimus A9 eluted from different stent platforms. To date, the pharmacokinetics of Biolimus A9 in patients following the deployment of BioMatrix II stents has not yet been studied METHODS: BioMatrix II stents were implanted into 27 patients with coronary artery disease. The primary endpoints of the study were the systemic concentrations of Biolimus A9 after 28 days and 6 months as measured using a sensitive validated liquid chromatography-tandem mass spectrometry assay. RESULTS: The highest measured blood concentration at any time point was 394 pg/mL. At 28 days and 6 months following stent placement, 51.8 and 100% of patients, respectively, had Biolimus A9 concentrations <10 pg/mL. After 9 months, 100% of the patients were free of major cardiac adverse events (MACE). There was no Biolimus A9 toxicity, no cardiac or non-cardiac deaths, no myocardial infarctions, nor target vessel or target lesion revascularizations during the 9 months of follow-up. No case of acute, subacute, or late stent thrombosis was detected. CONCLUSIONS: Compared to other drug-eluting stents, such as Cypher, BioMatrix II results in relatively low systemic exposure, which may be explained by the ablominal coating of the Biomatrix II stent in combination with Biolimus A9's high lipophilicity.
OBJECTIVES: This prospective, open-label multicenter study was conducted to assess the pharmacokinetics of Biolimus A9 after elution from BioMatrix II coronary stents. Recent clinical trials have demonstrated the efficacy and safety of Biolimus A9 eluted from different stent platforms. To date, the pharmacokinetics of Biolimus A9 in patients following the deployment of BioMatrix II stents has not yet been studied METHODS: BioMatrix II stents were implanted into 27 patients with coronary artery disease. The primary endpoints of the study were the systemic concentrations of Biolimus A9 after 28 days and 6 months as measured using a sensitive validated liquid chromatography-tandem mass spectrometry assay. RESULTS: The highest measured blood concentration at any time point was 394 pg/mL. At 28 days and 6 months following stent placement, 51.8 and 100% of patients, respectively, had Biolimus A9 concentrations <10 pg/mL. After 9 months, 100% of the patients were free of major cardiac adverse events (MACE). There was no Biolimus A9 toxicity, no cardiac or non-cardiac deaths, no myocardial infarctions, nor target vessel or target lesion revascularizations during the 9 months of follow-up. No case of acute, subacute, or late stent thrombosis was detected. CONCLUSIONS: Compared to other drug-eluting stents, such as Cypher, BioMatrix II results in relatively low systemic exposure, which may be explained by the ablominal coating of the Biomatrix II stent in combination with Biolimus A9's high lipophilicity.
Authors: U Christians; W Jacobsen; N Serkova; L Z Benet; C Vidal; K F Sewing; M P Manns; G I Kirchner Journal: J Chromatogr B Biomed Sci Appl Date: 2000-10-01
Authors: Stefan Verheye; Pierfrancesco Agostoni; Christophe L Dubois; Joseph Dens; John Ormiston; Stephen Worthley; Brett Trauthen; Takao Hasegawa; Bon-Kwon Koo; Peter J Fitzgerald; Roxana Mehran; Alexandra J Lansky Journal: J Am Coll Cardiol Date: 2009-03-24 Impact factor: 24.094
Authors: Joanna J Wykrzykowska; Patrick W Serruys; Yoshinobu Onuma; Ton de Vries; Gerrit-Anne van Es; Pawel Buszman; Axel Linke; Thomas Ischinger; Volker Klauss; Roberto Corti; Franz Eberli; William Wijns; Marie-Claude Morice; Carlo di Mario; Robert Jan van Geuns; Peter Juni; Stephan Windecker Journal: JACC Cardiovasc Interv Date: 2009-09 Impact factor: 11.195
Authors: Joanna J Wykrzykowska; Lorenz Räber; Ton de Vries; Marco Bressers; Pawel Buszman; Axel Linke; Thomas Ischinger; Volker Klauss; Franz Eberli; Roberto Corti; William Wijns; Marie-Claude Morice; Carlo di Mario; Evelyn Regar; Peter Jüni; Stephan Windecker; Patrick W Serruys Journal: EuroIntervention Date: 2009-08 Impact factor: 6.534
Authors: Pieter R Stella; Ralf Mueller; George Pavlakis; Bernard De Bruyne; Karl Hauptmann; Marie-Claude Morice; Bernard Chevalier; Jean Fajadet; Horst Sievert; Eberhard Grube Journal: EuroIntervention Date: 2008-08 Impact factor: 6.534